Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
Hepatology Research · 2024-08 · 54 (8) · 719-726
DOI: 10.1111/hepr.14078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 17.06.2024. Verfasst von Takanori Ito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Hospital, Nagoya, Japan. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical.
Abstract (Originalsprache)
With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI‐induced liver injury) as an immune‐related adverse event has become a major concern in clinical practice. Because severe cases of liver injury require administration of corticosteroids, a comprehensive evaluation is crucial, including clinical course, blood and imaging tests, and if necessary, pathological examination through liver biopsy. As with liver injury induced by other drugs, classification of injury type by R ‐value is useful in deciding treatment strategies for ICI‐induced liver injury. Histologically, the most representative feature is an acute hepatitis‐like hepatocellular injury, characterized by diffuse lobular inflammation accompanied by CD8‐positive T lymphocytes. Another condition that can cause liver injury during ICI treatment is cholangitis accompanied by non‐obstructive bile duct dilatation and bile duct wall thickening. Many cases of ICI‐induced cholangitis are classified as non‐hepatocellular injury type, and they have been reported to respond poorly to corticosteroids. It is essential that gastroenterologists/hepatologists and doctors in various departments work in cooperation to develop a system that achieves early diagnosis and appropriate treatment of ICI‐induced liver injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagoya University Hospital, Nagoya, Japan.
- Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
- Department of Gastroenterology, Niigata Cancer Center Hospital, Niigata, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
ORCID-Profile: Mina Komuta, Atsushi Tanaka
Förderung
- Chugai Pharmaceutical
Zitieren
APA
Ito, T., Takeuchi, Y., Mizuno, K., Imai, M., Yoshimaru, Y., Abe, K., Abe, M., Matsuura, T., Yokode, M., Shiokawa, M., Kodama, Y., Komuta, M., Harada, K., & Tanaka, A. (2024). Diagnostic guide for immune checkpoint inhibitor‐induced liver injury. Hepatology Research, 54(8), 719-726. https://doi.org/10.1111/hepr.14078
Vancouver
Ito T, Takeuchi Y, Mizuno K, Imai M, Yoshimaru Y, Abe K, et al. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury. Hepatology Research. 2024;54(8):719-726. doi:10.1111/hepr.14078
BibTeX
@article{Ito2024,
author = {Ito, Takanori and Takeuchi, Yasuto and Mizuno, Kazuyuki and Imai, Michitaka and Yoshimaru, Yoko and Abe, Kazumichi and Abe, Masanori and Matsuura, Takanori and Yokode, Masataka and Shiokawa, Masahiro and Kodama, Yuzo and Komuta, Mina and Harada, Kenichi and Tanaka, Atsushi},
title = {Diagnostic guide for immune checkpoint inhibitor‐induced liver injury},
journal = {Hepatology Research},
year = {2024},
volume = {54},
number = {8},
pages = {719--726},
doi = {10.1111/hepr.14078}
}
EUVIMED